Join
Live feed
·
PRReleasevia Quantisnow
Gracell Biotechnologies Inc. logo

Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients

ByQuantisnow·Wall Street's wire, on your screen.
GRCL· Gracell Biotechnologies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GRCL (Gracell Biotechnologies Inc.) and more on Quantisnow.